Stockscreener 앱 받기
54.81
1.59%
0.86
전일 마감가:
$53.95
열려 있는:
$54.1
하루 거래량:
660.41K
Relative Volume:
0.53
시가총액:
$3.92B
수익:
-
순이익/손실:
$-98.78M
주가수익비율:
-32.94
EPS:
-1.6638
순현금흐름:
$-65.60M
1주 성능:
+3.51%
1개월 성능:
+8.00%
6개월 성능:
+107.22%
1년 성능:
+191.39%
1일 변동 폭
$53.10
$55.81
1주일 범위
$52.00
$55.81
52주 변동 폭
$14.79
$55.81
Enliven Therapeutics Inc Stock (ELVN) Company Profile
명칭
Enliven Therapeutics Inc
전화
720-647-8519
주소
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
54.81 | 3.77B | 0 | -98.78M | -65.60M | -1.6638 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-16 | 개시 | Goldman | Buy |
| 2024-12-13 | 개시 | BTIG Research | Buy |
| 2024-09-09 | 개시 | H.C. Wainwright | Buy |
| 2024-06-11 | 개시 | Robert W. Baird | Outperform |
| 2024-04-09 | 개시 | Mizuho | Buy |
| 2023-03-29 | 개시 | Jefferies | Buy |
모두보기
Enliven Therapeutics Inc 주식(ELVN)의 최신 뉴스
Enliven Therapeutics Inc (ELVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enliven Therapeutics Inc (ELVN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ELVN|Enliven Therapeutics Inc|Price:52.750|Chg%:-0.200 - TradingKey
Enliven Therapeutics stock hits 52-week high at 54.9 USD - Investing.com
Enliven Therapeutics Inc (ELVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Enliven Therapeutics stock hits 52-week high at 54.9 USD By Investing.com - Investing.com Canada
Enliven Therapeutics Inc (ELVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enliven Therapeutics Inc (ELVN) Cash Flow - TradingKey
Enliven Therapeutics Inc (ELVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enliven Therapeutics Inc (ELVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enliven Therapeutics Inc (ELVN) Institutional Confidence - TradingKey
ELVN|Enliven Therapeutics Inc|Price:52.950|Chg%:+0.140 - TradingKey
Enliven Therapeutics, Inc. Revenue Breakdown – NASDAQ:ELVN - TradingView
TradingKey - TradingKey
Enliven Therapeutics Market Sentiment - Benzinga España
Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $67 - Moomoo
ELVN Maintained by Goldman Sachs -- Price Target Raised to $67.0 - GuruFocus
Enliven Therapeutics chief medical officer Collins sells $263k in shares - Investing.com UK
Enliven Therapeutics CFO Hohl sells $316,780 in stock - Investing.com India
Enliven Therapeutics chief medical officer Collins sells $263k in shares By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO Hohl sells $316,780 in stock By Investing.com - Investing.com South Africa
Form 4 Enliven Therapeutics Inc For: 21 July By Investing.com - Investing.com Canada
Enliven Therapeutics Insider Sold Shares Worth $263,373, According to a Recent SEC Filing - marketscreener.com
Enliven Therapeutics Insider Sold Shares Worth $316,780, According to a Recent SEC Filing - marketscreener.com
Enliven Therapeutics (NASDAQ: ELVN) CFO sells 6,018 shares after option exercise - Stock Titan
Enliven Therapeutics, Inc. (ELVN) CMO exercises options, sells 5,000 shares - Stock Titan
Enterprise value to revenue forward of Enliven Therapeutics, Inc. – NASDAQ:ELVN - TradingView
Enliven Therapeutics (ELVN) Slides 2.88% as Stock Tests Support LevelFundamentals - dars.gov.et
Enterprise value to EBIT forward of Enliven Therapeutics, Inc. – NASDAQ:ELVN - TradingView
Price to earnings forward of Enliven Therapeutics, Inc. – BOATS:ELVN - TradingView
How Enliven Therapeutics Inc. (ELVN) Affects Rotational Strategy Timing - Stock Traders Daily
Form 144 Enliven Therapeutics For: 17 July By Investing.com - Investing.com Nigeria
Enliven Therapeutics (ELVN) investor Helen Collins plans sale of 15,000 shares - Stock Titan
Enliven Therapeutics stock hits 52-week high at 52.47 USD By Investing.com - Investing.com Nigeria
Enliven Therapeutics stock hits 52-week high at 52.47 USD - Investing.com
Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know - MSN
H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $64 - Moomoo
Enliven Therapeutics Inc. (ELVN) Q1 2026 Earnings: EPS Beat Driven by Lower Operating Costs, Stock Slips on Lack of Pipeline CatalystsQuarterly Earnings - dars.gov.et
Enliven Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
H.C. Wainwright raises Enliven Therapeutics price target on trial data By Investing.com - Investing.com Canada
ELVN Maintained by HC Wainwright & Co. -- Price Target Raised to $64 - GuruFocus
Insider Sell Alert: Lori Kunkel Sells 10,000 Shares of Enliven T - GuruFocus
Enliven Therapeutics (ELVN) Fell Out Of Russell Indexes, But Is The Valuation Already Rich? - simplywall.st
Enliven Therapeutics Insider Sold Shares Worth $504,903, According to a Recent SEC Filing - marketscreener.com
Enliven Therapeutics (ELVN) director sells 10,000 shares under 10b5-1 plan - Stock Titan
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - AOL.com
Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value Lags - Yahoo Finance
Enliven Therapeutics Inc (ELVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Enliven Therapeutics Inc 주식 (ELVN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Jul 17 '26 |
Sale |
52.64 |
6,018 |
316,780 |
46,054 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
Jul 17 '26 |
Option Exercise |
2.48 |
5,000 |
12,400 |
30,000 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
Jul 17 '26 |
Sale |
52.67 |
5,000 |
263,373 |
25,000 |
2.44%
0.02%
자본화:
|
볼륨(24시간):